Stock Events

Haemonetics 

€67.5
2
+€0+0% Today

Statistics

Day High
67.5
Day Low
67.5
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
3.77B
P/E Ratio
29.76
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
0.67
0.8
0.92
1.05
Expected EPS
0.89
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HAZ.F. It's not an investment recommendation.

Analyst Ratings

99.5Average Price Target
The highest estimate is €105.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

About

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Show more...
CEO
Mr. Christopher A. Simon
Employees
3034
Country
US
ISIN
US4050241003
WKN
000881782

Listings